Skip to main content
SpringerLink
Log in

Cost Effectiveness of Venous Thromboembolism Pharmacological Prophylaxis in Total Hip and Knee Replacement: A Systematic Review

  • Correspondence
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kapoor A, Chuang W, Radhakrishnan N, et al. Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review. Pharmacoeconomics 2010; 28 (7): 521–38

    PubMed  Google Scholar 

  2. National Institute for Health and Clinical Excellence. Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults. Technology appraisal guidance 157. London: NICE, 2008 Sep

    Google Scholar 

  3. National Institute for Health and Clinical Excellence. Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults. Technology appraisal guidance 170. London: NICE, 2009 Apr

    Google Scholar 

  4. Scottish Medicines Consortium. Drug advice: dabigatran etexilate, 75 mg and 110mg hard capsules (Pradaxa®). Glasgow: SMC, 2008 May

  5. Scottish Medicines Consortium. Drug advice: rivaroxaban 10 mg film-coated tablets (Xarelto®). Glasgow: SMC, 2008 Nov

  6. Wolowacz SE, Roskell NS, Maciver F, et al. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism following total knee and hip replacement surgery. Clin Ther 2009; 31 (1): 194–212

    Article  PubMed  Google Scholar 

  7. Wolowacz SE, Roskell NS, Plumb JM, et al. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement. Thromb Haemost 2010; 103 (2): 360–71

    Article  PubMed  CAS  Google Scholar 

  8. Wolowacz SE, Hess N, Brennan VK, et al. Cost-effectiveness of venous thromboembolism prophylaxis in total hip and knee replacement surgery: the evolving application of health economic modelling over 20 years. Curr Med Res Opin 2008 Oct; 24 (10): 2993–3006

    Article  PubMed  CAS  Google Scholar 

  9. McCullagh L, Tilson L, Walsh C, et al. A cost-effectiveness analysis model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting. Pharmacoeconomics 2009; 27 (10): 829–46

    Article  PubMed  Google Scholar 

  10. Kakkar AK, Brenner B, Dahl OE, et al., RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372 (9632): 31–9

    Article  PubMed  CAS  Google Scholar 

  11. Lassen MR. Recent developments in the use of oral anticoagulants. Expert Opin Pharmacother 2009; 10 (11): 1769–81

    Article  PubMed  CAS  Google Scholar 

  12. Gómez-Outes A, Lecumberri R, Pozo C, et al. New anticoagulants: focus on venous thromboembolism. Curr Vasc Pharmacol 2009; 7 (3): 309–29

    Article  PubMed  Google Scholar 

  13. Merli G, Spyropoulos AC, Caprini JA. Use of emerging oral anticoagulants in clinical practice: translating results from clinical trials to orthopedic and general surgical patient populations. Ann Surg 2009; 250 (2): 219–28

    Article  PubMed  Google Scholar 

  14. Hull RD, Yusen RD, Bergqvist D. State-of-the-art review: assessing the safety profiles of new anticoagulants for major orthopedic surgery thromboprophylaxis. Clin Appl Thromb Hemost 2009; 15 (4): 377–88

    Article  PubMed  CAS  Google Scholar 

  15. Eriksson BI, Dahl OE, Rosencher N, et al., RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370 (9591): 949–56

    Article  PubMed  CAS  Google Scholar 

  16. Eriksson BI, Borris LC, Friedman RJ, et al., RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358 (26): 2765–75

    Article  PubMed  CAS  Google Scholar 

  17. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5 (11): 2178–85

    Article  PubMed  CAS  Google Scholar 

  18. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358 (26): 2776–86

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors are employees of Boehringer Ingelheim GmbH. Boehringer Ingelheim is the manufacturer of dabigatran etexilate (Pradaxa®).

Author information

Authors and Affiliations

  1. Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany

    Jonathan M. Plumb, Andreas Clemens & Brigitta U. Monz

Authors
  1. Jonathan M. Plumb
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas Clemens
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Brigitta U. Monz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Plumb, J.M., Clemens, A. & Monz, B.U. Cost Effectiveness of Venous Thromboembolism Pharmacological Prophylaxis in Total Hip and Knee Replacement: A Systematic Review. Pharmacoeconomics 28, 781–782 (2010). https://doi.org/10.2165/11535700-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11535700-000000000-00000

Keywords

Search

Navigation